PDCD1 and neoplasm: In another study, Stadmauer et al. isolated T-cells from two progressive stubborn myeloma patients and one advanced sarcoma patient and used CRISPR/Cas9 where they disrupt the TRAC, TRBC, and PDCD1 genes and inserted the NY–ESO-1 transgene (which recognize tumours) to get an improved antitumor immunity [24].